IDH1调控干扰素通路相关基因IFIT3的表达

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (7): 988-994.

IDH1调控干扰素通路相关基因IFIT3的表达

唐婉军¹, 彭小忠^1,2*, 韩为^1*

1.中国医学科学院基础医学研究所北京协和医学院基础学院生物化学与分子生物学系医学分子生物学国家重点实验室医学灵长类研究中心神经科学中心, 北京 100005;
2.中国医学科学院医学生物学研究所,云南昆明 650118

收稿日期:2021-04-20 修回日期:2021-05-18 出版日期:2021-07-05 发布日期:2021-06-17
通讯作者: *pengxiaozhong@pumc.edu.cn; hanwei2012@ibms.pumc.edu.cn
基金资助:
国家自然科学基金(21874156)

IDH1 regulates the expression of interferon pathway-related gene IFIT3

TANG Wan-jun¹, PENG Xiao-zhong^1,2*, HAN Wei^1*

1. State Key Laboratory of Medical Molecular Biology, Department of Molecular Biology and Biochemistry, Medical Primate Research Center, Neuroscience Center, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005;
2. Institute of Medical Biology CAMS, Kunming 650118, China

Received:2021-04-20 Revised:2021-05-18 Online:2021-07-05 Published:2021-06-17
Contact: *pengxiaozhong@pumc.edu.cn; hanwei2012@ibms.pumc.edu.cn

摘要/Abstract

摘要： 目的探究在人胶质瘤细胞系LN229中异柠檬酸脱氢酶1基因(IDH1)对RNA结合蛋白(RBPs)表达的影响。方法首先通过慢病毒感染构建IDH1稳定敲低和对照组LN229细胞株,分别对两组细胞株进行转录组测序(RNA-seq),利用limma包分析差异表达基因(DEGs)及其富集通路;然后通过string比对RBP数据库筛选出差异表达的RBPs,构建蛋白相互作用网络并挑选出候选RBPs;最后在IDH1敲低、过表达和R132H突变的细胞系中进行表达量验证。结果在IDH1敲低的LN229细胞株中,利用RNA-seq共筛选到259个DEGs,其中146个表达上调,113个表达下调;这些DEGs中包括14个编码RBP的基因,其中9个RBPs均为干扰素通路相关基因,并且具有密切的相互作用;与对照组相比,IDH1敲低时这9个RBPs表达水平均显著上调(P＜0.001), IDH1过表达时仅IFIT3表达显著下降(P＜0.01),而IDH1突变时IFIT3的表达水平的改变无统计学意义。结论在人胶质瘤细胞系LN229中,IDH1可调控干扰素通路相关基因IFIT3的表达。

关键词: 胶质瘤, IDH1, 干扰素通路, IFIT3

Abstract: Objective To explore the role of IDH1 in the expression of RNA binding proteins (RBPs) in glioma cell line LN229. Methods Lentivirus was used to construct IDH1 knockdown and control cells, and the expression of IDH1 was validated by RT-qPCR (real-time quantitative PCR) and Western blot. Then the total RNA of cells from each group was extracted for RNA sequencing (RNA-seq); the differentially expressed genes (DEGs) were identified by limma package and enriched pathways were analyzed; the differentially expressed RBPs were selected according to the RBP database and protein-protein interaction network was constructed by string database; finally, the expression level of candidate RBPs was tested in IDH1 knockdown, over-expressed and mutant cells(R132H) respectively. Results A total of 259 DEGs were detected in IDH1 knockdown LN229 cells, including 146 upregulated and 113 downregulated genes. These DEGs were significantly enriched in interferon related pathways and included 14 RBP-encoding genes, 9 of which were significantly enriched in interferon related pathways and showed close interaction; compared with the control group, IDH1 knockdown in LN229 significantly upregulated the expression of all the nine RBPs (P＜0.001), and IDH1 overexpression only downregulated IFIT3 (P＜0.01) involving in interferon pathway, while IDH1 mutation had no significant effect on IFIT3. Conclusions IDH1 regulates expression of interferon pathway related gene IFIT3 in LN229 cells.

Key words: glioma, IDH1, interferon pathway, IFIT3

中图分类号:

唐婉军, 彭小忠, 韩为. IDH1调控干扰素通路相关基因IFIT3的表达[J]. 基础医学与临床, 2021, 41(7): 988-994.

TANG Wan-jun, PENG Xiao-zhong, HAN Wei. IDH1 regulates the expression of interferon pathway-related gene IFIT3[J]. Basic & Clinical Medicine, 2021, 41(7): 988-994.

参考文献

[1]Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131:803-820.
[2]Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas[J]. Acta Neuropathol, 2015, 129:585-596.
[3]Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 2009, 360:765-773.
[4]Lunde BM, Moore C, Varani G, et al. RNA-binding proteins: modular design for efficient function[J]. Nat Rev Mol Cell Biol, 2007, 8:479-490.
[5]Brinegar AE, Cooper TA. Roles for RNA-binding proteins in development and disease[J]. Brain Res, 2016, 1647:1-8.
[6]Wang ZX, Tang WJ, Yuan JG, et al. Integrated analysis of RNA-binding proteins in glioma[J]. Cancers, 2020, 12: 892. doi: 10.3390/cancers12040892.
[7]Calvert AE, Chalastanis A, Wu Y, et al. Cancer-associa-ted IDH1 promotes growth and resistance to targeted therapies in the absence of mutation[J]. Cell Rep, 2017, 19:1858-1873.
[8]Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate[J]. Nature, 2009, 462:739-744.
[9]Yang Z, Liang H, Zhou Q, et al. Crystal structure of ISG54 reveals a novel RNA binding structure and potential functional mechanisms[J]. Cell Res, 2012, 22:1328-1338.
[10]Pidugu VK, Pidugu HB, Wu MM, et al. Emerging functions of human IFIT proteins in cancer[J]. Front Mol Biosci, 2019, 6:148. doi: 10.3389/fmolb.2019.00148.
[11]Zhang JF, Chen Y, Lin GS, et al. High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma[J]. Hum Pathol, 2016, 52:136-144.
[12]Lai KC, Chang KW, Liu CJ, et al. IFN-induced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma[J]. Mol Cancer Res, 2008, 6:1431-1439.
[13]Shu X, Dong Li, Hai QZ, et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins[J]. Proc Natl Acad Sci, 2006, 103:16448-16453.
[14]Lo UG, Pong RC, Yang D, et al. IFNgamma-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing[J]. Cancer Res, 2019, 79:1098-1112.